Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4363572 | 0.82 | MEN1 (0.56) | KDM4ELMNAMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL9699046 | 0.80 | KDM4E (0.56) | KDM4ELMNAMAPK1L3MBTL1EPHX1 | |
| SCHEMBL4366694 | 0.79 | MEN1 (0.56) | KDM4ELMNAMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL4366695 | 0.78 | LTA4H (0.61) | LMNAMAPK1L3MBTL1SMN1; SMN2TP53 | |
| SCHEMBL4363576 | 0.78 | LTA4H (0.61) | LMNAMAPK1L3MBTL1SMN1; SMN2TP53 | |
| SCHEMBL11768063 | 0.77 | KDM4E (0.60) | KDM4ELMNAL3MBTL1EPHX1SMN1; SMN2 | |
| SCHEMBL4844621 | 0.77 | KDM4E (0.70) | KDM4ELMNAL3MBTL1SMN1; SMN2TP53 | |
| SCHEMBL16961553 | 0.77 | KDM4E (0.69) | KDM4ELMNAL3MBTL1EPHX1SMN1; SMN2 | |
| SCHEMBL16090169 | 0.76 | POLB (0.63) | KDM4ELMNAMAPK1L3MBTL1SMN1; SMN2 | |
| SCHEMBL20496426 | 0.75 | KDM4E (0.62) | KDM4ELMNAMAPK1L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145435-A2 | LIPID COMPOSITIONS AND METHODS FOR DELIVERY TO IMMUNE CELLS | Life Technologies Corporation (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20230181742-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | Life Technologies Corporation | 2023-06-15 | — | — | US | disclosed |
| US-20200061197-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | Life Technologies Corporation | 2020-02-27 | — | — | US | disclosed |
| US-10406237-B2 | Amine-containing transfection reagents and methods for making and using same | LIFE TECHNOLOLGIES CORPORATION (US) | 2019-09-10 | — | — | US | disclosed |
| EP-3470395-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | Life Technologies Corporation (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-2640700-B1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | LIFE TECHNOLOGIES CORP (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20180200374-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | Life Technologies Corporation | 2018-07-19 | — | — | US | disclosed |
| US-9901642-B2 | Amine-containing transfection reagents and methods for making and using same | Life Technologies Corporation (US) | 2018-02-27 | — | — | US | disclosed |
| US-20150174260-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | Life Technologies Corporation | 2015-06-25 | — | — | US | disclosed |
| EP-2640700-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | Life Technologies Corporation (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012068176-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | Life Technologies Corporation (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2011-03-03 | — | — | US | disclosed |
| EP-2244694-A2 | THERAPEUTIC COMPOSITIONS COMPRISING AN AMINE-CONTAINING LIPID AND A PROTEIN | Shire Human Genetic Therapies, Inc. (US) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009097332-A2 | THERAPEUTIC COMPOSITIONS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
| EP-1912679-A4 | AMINE-CONTAINING LIPIDS AND USES THEREOF | MASSACHUSETTS INST TECHNOLOGY (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1912679-A2 | AMINE-CONTAINING LIPIDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2006138380-A2 | AMINE-CONTAINING LIPIDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174260-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | SNRPA, NUDT21, SOAT2 | KDM4E 3222/4885LMNA 167/4885MAPK1 4045/4885 |
| US-10406237-B2 | Amine-containing transfection reagents and methods for making and using same | SNRPA, NUDT21, SOAT2 | KDM4E 3222/4885LMNA 167/4885MAPK1 4045/4885 |
| US-20230181742-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | SNRPA, NUDT21, SOAT2 | KDM4E 3222/4885LMNA 167/4885MAPK1 4045/4885 |
| US-20200061197-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | SNRPA, NUDT21, SOAT2 | KDM4E 3222/4885LMNA 167/4885MAPK1 4045/4885 |
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | PHOSPHO1, SGMS1, APOB | KDM4E 2558/4885LMNA 536/4885MAPK1 4317/4885 |
| US-20180200374-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | SNRPA, NUDT21, SOAT2 | KDM4E 3222/4885LMNA 167/4885MAPK1 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.